Tesamorelin in Canada: What It Is, What the Trial Found, Where to Get It
Tesamorelin is the rare peptide with a Canadian story and a proper clinical trial behind it. It was developed by a Montreal company, approved by Health Canada, and tested in a randomised trial of more than 400 people before anyone in a gym had heard of it. That makes it easier to talk about honestl…
In this article
Tesamorelin is the rare peptide with a Canadian story and a proper clinical trial behind it. It was developed by a Montreal company, approved by Health Canada, and tested in a randomised trial of more than 400 people before anyone in a gym had heard of it.
That makes it easier to talk about honestly than most of what sits on a peptide shelf. Here is what it is, what the trial found, how it compares to the other growth hormone options, and what it costs to get in Canada.
What tesamorelin is
Tesamorelin is a synthetic version of growth hormone releasing hormone, the signal your hypothalamus sends to tell the pituitary to release growth hormone. It is a 44 amino acid peptide with a small chemical change at one end that makes it last longer in the body than the natural hormone.
It does not contain growth hormone. It tells your own pituitary to make more, in the same pulsing pattern your body already uses. Downstream, the liver turns that into IGF-1.
That mechanism is the whole reason people are interested. It is closer to natural growth hormone release than injecting HGH directly.
The Canadian part
Tesamorelin was developed by Theratechnologies, a pharmaceutical company based in Montreal, and sold under the brand name Egrifta.
The FDA approved it in November 2010. Health Canada approved it in April 2014, for one specific use: reducing excess abdominal fat in adults with HIV who have built up visceral fat as a side effect of treatment.
That is the only approved use. Everything else people talk about, recomposition, fat loss outside HIV, recovery, is off label or research use.
What the trial actually found
The study behind the approval was published in the New England Journal of Medicine in 2007. 412 patients were given either 2 mg of tesamorelin a day by injection under the skin, or a placebo, for 26 weeks.
| After 26 weeks | Tesamorelin | Placebo |
|---|---|---|
| Visceral (belly) fat | Down 15.2% | Up 5.0% |
| IGF-1 | Up 81% | Down 5% |
| Blood sugar measures | No significant difference | No significant difference |
Two things are worth reading closely. The fat it moved was visceral fat, the deep fat around the organs, not the fat you can pinch. And unlike most growth hormone approaches, it did not produce a significant change in blood sugar markers over the trial.
Side effects the trial reported
The number of overall and serious side effects was not significantly higher than placebo. What did show up:
- Injection site reactions, redness and itching where it goes in, the most common complaint.
- Hives spreading beyond the injection site in about 2% of people on tesamorelin.
- Antibodies against tesamorelin in roughly half of the people taking it. The trial did not link these to a loss of effect, but it is a reason not to treat it as something you take forever without bloodwork.
- A larger share of people on tesamorelin stopped the study early because of a side effect than on placebo.
Because it raises IGF-1, the usual growth hormone cautions apply. It is not for anyone with active cancer, and it is not for use in pregnancy.
Tesamorelin against the other options
| Tesamorelin | HGH | CJC-1295 + Ipamorelin | MK-677 | |
|---|---|---|---|---|
| What it is | GHRH analogue | Growth hormone itself | GHRH analogue + GH secretagogue | Oral GH secretagogue |
| How it works | Signals the pituitary | Supplies the hormone | Signals the pituitary from two directions | Mimics ghrelin to signal the pituitary |
| Route | Injection | Injection | Injection | Oral |
| Human trial data | Strong, approved drug | Strong, approved drug | Limited | Moderate |
| Main effect people want | Visceral fat | Broad GH effects | GH pulse, recovery, sleep | GH, appetite, sleep |
If the reason you are looking is stubborn belly fat, tesamorelin is the one with direct evidence for exactly that. If it is broader growth hormone effects, read how to dose HGH properly and the HGH myths piece, and our comparison of peptides and steroids.
Getting tesamorelin in Canada
As a prescription. Egrifta is a prescription drug in Canada, approved for the HIV indication above. Outside that use it is hard to get prescribed, and it is expensive. Canada’s drug review agency recommended against public coverage for it.
As a research peptide. This is how most people outside that indication get it. We stock tesamorelin at $65, sold for research purposes.
It comes as a freeze-dried powder and has to be reconstituted before use. You will need bacteriostatic water ($10) to do that. Once mixed it goes in the fridge.
If you are stacking it with other growth hormone peptides, the CJC-1295 + Ipamorelin blend is the other one people most often look at.
Common questions
Is tesamorelin approved in Canada?
Yes, as Egrifta, since April 2014, for excess visceral fat in adults with HIV. It is not approved for any other use.
What dose was used in the trial?
2 mg once a day, by injection under the skin, for 26 weeks. That is published trial data, not a recommendation.
Does tesamorelin burn belly fat?
In the trial it reduced visceral fat by about 15% over six months against a small increase on placebo. That is fat around the organs, not general body fat.
Is tesamorelin the same as HGH?
No. It contains no growth hormone. It tells your pituitary to release more of its own.
Does it affect blood sugar?
The trial found no significant change in blood sugar measures. If you already have blood sugar issues, test anyway.
The short version
Tesamorelin is a GHRH analogue made in Montreal, approved by Health Canada in 2014, and backed by a 412 person trial that showed a 15% drop in visceral fat over six months. It works through your own pituitary rather than replacing growth hormone. Tesamorelin is $65 here, with bacteriostatic water to reconstitute it.
Sold for research purposes only. Our research peptide is not Egrifta and is not approved by Health Canada for human use. Nothing on this page is medical advice. Trial figures are from Falutz et al., New England Journal of Medicine, 2007; approval dates from Health Canada and the FDA.
Keep reading
What Thymosin Alpha-1 Does and What the Trials Found
Thymosin alpha 1 gets lumped in with healing peptides like BPC-157 and TB-500, mostly because of the name. It is a different thing. It does not repair tissue. It is an immune pepti...
Read articleWhat Is Cagrilintide?
A weekly amylin shot that, paired with semaglutide, produced 22.7 percent weight loss in REDEFINE 1. How it works, the side effects, and where approval stands.
Read articleLetrozole (Femara): The AI of Last Resort, and How to Not Crash
The strongest of the three aromatase inhibitors, the only one that reverses gyno, and the one most likely to leave you with no oestrogen at all.
Read article